Anvisa authorized, on Monday (2/8), the realization of the clinical study to evaluate the safety and efficacy of the drug leronlimab for the treatment of moderately ill patients with pneumonia caused by Covid-19. Leronlimab is a monoclonal antibody that acts as a competitive inhibitor, blocking cell infection.